Voyageur Pharmaceuticals Ltd.
VM.V
TSX
| 11/30/2025 | 08/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -93.75% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -93.75% | -- | |||
| Cost of Revenue | -115.84% | -- | |||
| Gross Profit | 195.24% | -- | |||
| SG&A Expenses | -26.93% | 189.79% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -28.07% | 193.44% | |||
| Operating Income | 27.38% | -190.44% | |||
| Income Before Tax | 34.79% | -145.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.79% | -145.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.79% | -145.72% | |||
| EBIT | 27.38% | -190.44% | |||
| EBITDA | 27.39% | -190.58% | |||
| EPS Basic | 38.60% | -137.50% | |||
| Normalized Basic EPS | 38.89% | -140.00% | |||
| EPS Diluted | 38.60% | -137.50% | |||
| Normalized Diluted EPS | 38.89% | -140.00% | |||
| Average Basic Shares Outstanding | 6.52% | 3.90% | |||
| Average Diluted Shares Outstanding | 6.52% | 3.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||